CAT

716.12

+2.22%↑

GE

290.19

-0.82%↓

RTX

193.97

-0.3%↓

GEV.US

908.17

+3.08%↑

BA

196.1

-1.24%↓

CAT

716.12

+2.22%↑

GE

290.19

-0.82%↓

RTX

193.97

-0.3%↓

GEV.US

908.17

+3.08%↑

BA

196.1

-1.24%↓

CAT

716.12

+2.22%↑

GE

290.19

-0.82%↓

RTX

193.97

-0.3%↓

GEV.US

908.17

+3.08%↑

BA

196.1

-1.24%↓

CAT

716.12

+2.22%↑

GE

290.19

-0.82%↓

RTX

193.97

-0.3%↓

GEV.US

908.17

+3.08%↑

BA

196.1

-1.24%↓

CAT

716.12

+2.22%↑

GE

290.19

-0.82%↓

RTX

193.97

-0.3%↓

GEV.US

908.17

+3.08%↑

BA

196.1

-1.24%↓

Search

John Wiley & Sons Inc

Ouvert

SecteurIndustrie

0

Résumé

Variation du prix de l'action

24h

Actuel

Min

Max

Chiffres clés

By Trading Economics

Revenu

-15M

30M

Ventes

-12M

410M

P/E

Moyenne du Secteur

19.615

61.065

Rendement du dividende

3.86

Marge bénéficiaire

7.238

Employés

5,200

EBITDA

-202K

105M

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.86%

2.23%

Prochains Résultats

16 juin 2026

Date du Prochain Dividende

23 avr. 2026

Date du Prochain Détachement de Dividende

7 avr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

325M

1.9B

Ouverture précédente

0

Clôture précédente

0

Sentiment de l'Actualité

By Acuity

50%

50%

177 / 406 Classement par Industrials

John Wiley & Sons Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

23 mars 2026, 23:47 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mars 2026, 22:55 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mars 2026, 21:51 UTC

Acquisitions, Fusions, Rachats

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mars 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23 mars 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mars 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mars 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mars 2026, 22:42 UTC

Market Talk
Principaux Événements d'Actualité

Global Equities Roundup: Market Talk

23 mars 2026, 22:42 UTC

Market Talk
Principaux Événements d'Actualité

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mars 2026, 22:40 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mars 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mars 2026, 22:22 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mars 2026, 22:21 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mars 2026, 22:21 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mars 2026, 22:20 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mars 2026, 22:20 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mars 2026, 22:19 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mars 2026, 22:19 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mars 2026, 22:18 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mars 2026, 22:15 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mars 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mars 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 mars 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mars 2026, 21:32 UTC

Résultats

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mars 2026, 21:32 UTC

Résultats

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mars 2026, 21:32 UTC

Résultats

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mars 2026, 21:10 UTC

Principaux Événements d'Actualité

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mars 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23 mars 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23 mars 2026, 20:50 UTC

Market Talk
Résultats
Principaux Événements d'Actualité

Basic Materials Roundup: Market Talk

Comparaison

Variation de prix

John Wiley & Sons Inc prévision

Note du Consensus

By TipRanks

0 ratings

0

Achat

0

Maintien

0

Vente

Sentiment

By Acuity

177 / 406Classement par Industrie

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos John Wiley & Sons Inc

John Wiley & Sons, Inc. operates as a research and learning company worldwide. It operates through three segments: Research, Learning, and Held for Sale or Sold. The company offers scientific, technical, medical, and scholarly journals, as well as related content and services to learned societies, individual researchers, other professionals, as well as academic, corporate, and government libraries. It publishes physical sciences and engineering, health sciences, social sciences, and humanities and life sciences journals through research libraries and library consortia, and independent subscription agents, direct to professional society members, and other customers ; and operates Literatum, an online publishing platform for production and content hosting, submissions and peer review support, editorial, and copyediting services. The company also offers academic and professional products and services, including scientific, professional, education print and digital books, and digital courseware to libraries, corporations, students, professionals, and researchers through chain and online booksellers, libraries, colleges and universities, corporations, direct to consumer, websites, distributor networks, and other online applications. In addition, it provides learning, development, publishing, and assessment services to businesses and professionals; and online learning and training solutions for global corporations and small and medium-sized enterprises. John Wiley & Sons, Inc. was formerly known as John Wiley And Sons and changed its name to John Wiley & Sons, Inc. in November 1953. The company was founded in 1807 and is based in Hoboken, New Jersey.
help-icon Live chat